A Blood Test That Detects 50 Cancers Is Getting Its Full Trial Results

Most cancer screening programmes work on a single cancer at a time. The NHS-Galleri trial, which enrolled more than 140,000 volunteers in England between 2021 and 2023, tested something different: a single blood draw detecting signals from over 50 types of cancer simultaneously, years before symptoms appear.

The trial, coordinated by the Cancer Research UK Cancer Prevention Trials Unit at Queen Mary University of London and funded by GRAIL Bio UK, is now reporting its full results. The data will determine whether the NHS incorporates the Galleri test into its national screening programme, a decision that would affect millions of people and alter how cancer gets caught in one of the world's largest public health systems.

How the Test Works

Tumours shed fragments of DNA into the bloodstream as cells die and divide. These fragments, known as cell-free DNA or cfDNA, carry chemical modifications called methylation patterns that differ from normal circulating DNA. GRAIL's Galleri test analyses these methylation patterns using machine learning to identify which tissue the signal originated from, allowing it to detect not just the presence of a tumour signal but the likely location in the body.

This is where the test differs from previous multi-cancer detection attempts. Earlier approaches could identify a cancer signal but could not localise it, creating a real clinical problem: a positive result with no location means imaging the entire body, a costly and radiation-intensive process. Galleri's tissue-of-origin capability narrows the diagnostic follow-up considerably.

The test's sensitivity varies by cancer type and by stage. Published interim data from the trial, reported in The Lancet in late 2023, showed detection rates ranging from around 17% for early-stage disease to over 90% for late-stage cancers. The clinical argument for early detection is that catching cancer at stage one, when it is localised, produces dramatically better outcomes than catching it at stage four. A test with modest early-stage sensitivity but strong overall performance could still shift the distribution of diagnoses toward earlier, more treatable stages.

What the Early Data Showed

"The Galleri test detected approximately two-thirds of cancers across all stages in the trial cohort," according to findings presented to Cancer Research UK in 2023. "Performance was strongest for cancer types with historically poor early detection records, including pancreatic, head and neck, bowel, lung, and throat cancers."

Pancreatic cancer is the clearest example. There is currently no population-level screening programme for pancreatic cancer in Australia or the United Kingdom. About 85% of pancreatic cancer cases are diagnosed at stage three or four, when five-year survival rates sit around 3%. A test detecting pancreatic cancer signals at stage one or two, when surgical resection remains possible, would represent a genuine improvement in outcomes for a cancer that currently kills most of the people it reaches.

If You Are in Australia

Australia does not have an equivalent programme running at scale. The National Cancer Screening Register administers bowel and cervical screening. BreastScreen Australia runs the mammography programme. Cancer Australia, the federal body responsible for cancer control policy, monitors international trials but has not announced a Galleri-equivalent study.

If the NHS trial produces strong results this year, the standard pathway is for Cancer Australia to commission a feasibility study or pilot, typically a three-to-five year process. The test itself is commercially available in the United States, where GRAIL markets it at around $US950 per test, though Australian oncologists have generally been cautious about recommending it outside a trial context, citing the absence of local population data and Medicare rebates.

For Australians aged 50 and above who are concerned about cancer risk, the practical position right now is straightforward: the trial results will arrive this year and will tell far more about real-world performance than the interim data. Waiting for those results before seeking the test privately is the reasonable approach.

The Insurance and Financial Planning Angle

Early detection technology creates a specific tension with life and health insurance. In Australia, life insurers can legally ask about cancer diagnoses and factor them into policy pricing under the Insurance Contracts Act. A blood test revealing a cancer signal before symptoms appear creates a grey area: does a preclinical detection constitute a 'diagnosis' requiring disclosure? The Australian Prudential Regulation Authority and the Financial Services Council have not issued specific guidance on multi-cancer early detection tests.

This is not a trivial concern. If the test becomes commercially available and widely used, people who test positive may face adverse insurance outcomes before any clinical diagnosis, during a period when follow-up investigations are still ongoing. Financial planners advising clients who are considering private access to the Galleri test should flag this issue clearly before the client proceeds.

"We recommend that anyone who receives a Galleri test result consult with a physician before making any disclosures to insurers," GRAIL said in its US consumer guidance. "The regulatory framework for preclinical detection results and insurance disclosure obligations varies by jurisdiction."

The Full Results

The NHS-Galleri trial was designed to follow participants across three appointments over roughly two years, comparing cancer detection rates in the group offered the test against a control group receiving standard care only. Full results, the data that will determine whether this becomes an NHS-funded screening programme, are expected in 2026. They may take somewhat longer if the trial's data analysis team requires additional time.

If the results support adoption, the NHS would be the first national health system to implement multi-cancer early detection at population scale. That decision would accelerate evaluations in Canada, Australia, and across Europe. The question of when Australians will have routine access to this test through the public health system is a matter of years, not decades. What arrives from the NHS trial this year will determine where in that range the answer falls.